ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0717

Treatment Utilization in Dermatomyositis: An Analysis of Electronic Medical Records in the United States

Adrian Kielhorn1, Zheng Wang1, Kristin Moy1, Lisa Christopher-Stine2, Ingrid Lundberg3, Hector Chinoy4, Kaniah Gunter5 and Rohit Aggarwal6, 1Alexion, AstraZeneca Rare Disease, Boston, MA, 2Johns Hopkins University, Baltimore, MD, 3Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 4The University of Manchester, Sale, United Kingdom, 5Patient Author, Norfolk, VA, 6Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, dermatomyositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster I

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Dermatomyositis (DM) is a rare, chronic inflammatory disease characterized by skin manifestations and/or progressive muscle weakness and other systemic manifestations. Patients with DM were reported to have higher morbidity, hospitalization rates, and mortality than matched controls; however, more recent data on the disease burden and treatments for DM are warranted. This analysis was done to provide an updated understanding of the characteristics and treatment utilization among patients with myopathic DM in the United States.

Methods: This descriptive, retrospective cohort analysis used TriNetX US electronic medical records data to assess the characteristics and treatment utilization of adults with myopathic DM. Key inclusion criteria were DM diagnosis (ICD-9: 710.3/ICD-10: M33.1x, M33.9x, M36.0) between 1 January 2007 and 1 September 2020; age ≥18 years at index diagnosis; ≥6 months of baseline data before the index diagnosis date; and ≥6 months of follow-up after the index date. Assessments included utilization rates of medications of interest prior to DM index diagnosis; percentage of patients who received ≥2 consecutive unique non-steroidal immunosuppressive therapies within 3, 6, and 12 months of DM index diagnosis; and classification and qualification of most common post-index symptoms and comorbidities and comparisons to pre-index rates.

Results: The TriNetX database contained 1097 patients with DM (mean age, 54.6 y; female, 77%). The mean observation period was 9.7 y (6.0 y pre-index; 3.7 y post-index). Prior to the DM index date, 60% of patients were prescribed steroids and 24% were prescribed ≥1 non-steroidal immunosuppressive therapy. Within 3, 6, and 12 months of index date, 8%, 14%, and 20% of patients, respectively, received ≥2 immunosuppressive therapies. A 2–3-fold increase post-index compared with pre-index was seen for a wide range of symptoms and comorbidities, including gastroesophageal reflux disease (43% and 22%, respectively), anxiety (25% and 13%), interstitial lung diseases (26% and 10%), and osteoporosis (21% and 6%).

Conclusion: Most patients’ symptoms were treated with immunosuppressive therapies for an extended time before receiving a formal diagnosis of DM, which may contribute to the delayed diagnosis; some had received ≥2 immunosuppressive therapies at 1 y post-diagnosis. Symptoms and comorbidities increased post-diagnosis. Given the high number of patients receiving ≥2 immunosuppressive therapies at 1 y post-diagnosis and the comorbidities, DM is difficult to treat effectively with existing therapies. Thus, there is a high unmet need for earlier diagnosis and better symptom control, including with therapies with novel mechanisms of action.


Disclosures: A. Kielhorn, Alexion, AstraZeneca Rare Disease; Z. Wang, Alexion, AstraZeneca Rare Disease; K. Moy, Alexion, AstraZeneca Rare Disease; L. Christopher-Stine, Janssen, Boehringer-Ingelheim, Mallinckroft, EMD-Serono, Allogene, ArgenX; I. Lundberg, Argenx, AstraZeneca, Bristol Myers Squibb, Novartis, Corbus, EMD Serono, Roche, Pfizer, Orphazyme, Octapharma, Kezar, Janssen; H. Chinoy, Eli Lilly, UCB; K. Gunter, Alexion, AstraZeneca Rare Disease, Argenx, EMD Serono; R. Aggarwal, Mallinckrodt, Bristol Myers Squibb, EMD Serono, Pfizer, Octapharma, CSL Behring, Q32, Kezar, AstraZeneca, Alexion, Argenx, Boehringer Ingelheim, Corbus, Janssen, Kyverna, Roivant, AbbVie, Jubilant, Orphazyme, Genentech.

To cite this abstract in AMA style:

Kielhorn A, Wang Z, Moy K, Christopher-Stine L, Lundberg I, Chinoy H, Gunter K, Aggarwal R. Treatment Utilization in Dermatomyositis: An Analysis of Electronic Medical Records in the United States [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/treatment-utilization-in-dermatomyositis-an-analysis-of-electronic-medical-records-in-the-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-utilization-in-dermatomyositis-an-analysis-of-electronic-medical-records-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology